Search

Displaying results 5141 - 5150 of 10000 in total
  1. Drug

    Roxithromycin

    go.drugbank.com/drugs/DB00778
    ApprovedInvestigationalWithdrawn

    It is marketed in Australia as a treatment for respiratory tract, urinary and soft tissue infections. … Roxithromycin is a semi-synthethic macrolide antibiotic that is structurally and pharmacologically similar to [erythromycin], [azithromycin], or [clarithromycin].

    International brands: Bi Ai Di, I-ThrocinProducts: RULID D TABLETAS PARA SUSPENSION ORAL, ROXI 150 1A PHARMA
  2. Drug

    PR-104

    go.drugbank.com/drugs/DB05968
    Investigational

  3. Drug

    Dapansutrile

    go.drugbank.com/drugs/DB16130
    Investigational

    Dapansutrile is under investigation in clinical trial NCT01768975 (Phase 2 Efficacy Trial of OLT1177 Gel in Subjects With Moderate to Severe Pain Associated With OA of the Knee).

  4. Drug

    Pirenzepine

    go.drugbank.com/drugs/DB00670
    ApprovedWithdrawn

    It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. … It also potentiates the effect of other antiulcer agents such as cimetidine and ranitidine. It is generally well tolerated by patients.

    International brands: Pin
  5. Drug

    Succinobucol

    go.drugbank.com/drugs/DB05399
    Investigational

    AGI-1067, is a novel small molecule with anti-oxidant and anti-inflammatory properties that was discovered by AtheroGenics and designed to treat atherosclerosis of the blood vessels of the heart, or coronary

  6. Drug

    Iocarmic acid

    go.drugbank.com/drugs/DB13755
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Labetuzumab

    go.drugbank.com/drugs/DB05097
    Investigational

    Labetuzumab is a humanized monoclonal antibody to carcinoembryonic antigen that inhibits tumor growth. It is used in radioimmunotherapy.

  8. Drug

    GT 389-255

    go.drugbank.com/drugs/DB05894
    Experimental

    MAD) Phase I trials. … Peptimmune’s lead product GT 389-255, is a novel lipase inhibitor and fat binding hydrogel polymer conjugate for the treatment of obesity which has completed single and multiple ascending dose (SAD and

  9. Drug

    Scutellaria lateriflora

    go.drugbank.com/drugs/DB14339
    Approved

    Scutellaria lateriflora is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  10. Drug

    Nangibotide

    go.drugbank.com/drugs/DB16247
    Investigational

    Nangibotide is under investigation in clinical trial NCT04055909 (Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock).